My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

BioMarin Pharmaceutical Inc. - Common Stock (NQ:BMRN)

52.00 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Dec 18, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about BioMarin Pharmaceutical Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

16 17 Next >

7 Biotech Stocks Fighting America’s Deadliest Diseases ↗

February 08, 2024

Although the human condition can be alarmingly frail at times, these groundbreaking biotech stocks are aiming to right the ship.

Via InvestorPlace

3 No-Brainer Stocks to Buy With $200 Right Now ↗

February 07, 2024

A reasonably small amount of money can go a long way when it's put to work in innovative, industry-leading businesses.

Via The Motley Fool

Decoding 8 Analyst Evaluations For Biomarin Pharmaceutical ↗

January 30, 2024

Via Benzinga

4 Marvelous Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip ↗

January 20, 2024

A greater than 7% decline in the Nasdaq Composite from its record high signals that opportunistic investors can still find bargains.

Via The Motley Fool

Topics Stocks

If You Can Only Buy One Biotech Stock in January, It Better Be One of These 3 Names ↗

January 10, 2024

Biotech is one of the areas of interest in the market today, adding a biotech stock could be huge play this month.

Via InvestorPlace

Cracking The Code: Understanding Analyst Reviews For Biomarin Pharmaceutical ↗

December 21, 2023

Via Benzinga

Earnings Outlook For Biomarin Pharmaceutical ↗

October 31, 2023

Via Benzinga

15 Analysts Have This to Say About Biomarin Pharmaceutical ↗

October 16, 2023

Via Benzinga

What 16 Analyst Ratings Have To Say About Biomarin Pharmaceutical ↗

September 13, 2023

Via Benzinga

4 Preeminent Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip ↗

December 02, 2023

An 11% decline in the Nasdaq Composite over the past two years is an open invitation for opportunistic growth investors to go shopping.

Via The Motley Fool

Topics Stocks

Under the Microscope: 3 Biotech Stocks Pioneering Tomorrow’s Cures ↗

November 09, 2023

Unveil the resilience of biotech stocks as they outsmart market trends and champion the race for tomorrow's treatments.

Via InvestorPlace

3 Promising Biotech Stocks Flying Under the Radar ↗

November 08, 2023

Breakthroughs in healthcare are happening everyday, make sure you are keeping up to date on these under the radar biotech stocks.

Via InvestorPlace

BioMarin Surges As Activist Investor Elliott Reportedly Builds $1 Billion Stake ↗

November 07, 2023

The company's recently FDA-approved gene therapy is struggling to gain traction.

Via Investor's Business Daily

Datadog, Tripadvisor, Myriad Genetics, Planet Fitness And Other Big Stocks Moving Higher On Tuesday ↗

November 07, 2023

U.S. stocks traded mostly higher, with the Nasdaq Composite gaining around 50 points on Tuesday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Topics Stocks

Earnings Outlook For Biomarin Pharmaceutical ↗

July 28, 2023

Via Benzinga

4 Unique Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip ↗

November 04, 2023

A 19% decline in the Nasdaq Composite over the past two years represents an ideal time for opportunistic long-term investors to go shopping for bargains.

Via The Motley Fool

Topics Stocks

Why Is Gene Therapy Player PTC Therapeutics Stock Plunging Today? ↗

October 27, 2023

In its Q3 earnings release, PTC Therapeutics Inc (NASDAQ: PTCT) reported a

Via Benzinga

3 Under-the-Radar Biotech Stocks to Buy in 2023 ↗

October 19, 2023

These three lesser-known biotech companies are profitable and growing revenue.

Via The Motley Fool

Impact on BioMarin's Sentiment: Voxzogo's Triumph Clouded by Uncertainty ↗

September 28, 2023

Raymond James initiated coverage on BioMarin Pharmaceuticals Inc (NASDAQ: BMRN) with a Market Perform rating, noting sparsity in

Via Benzinga

Are Gene Therapy Stocks The Market's Next Big Winners?

September 25, 2023

Biotechs Sarepta and BioMarin are among companies advancing cutting-edge gene therapies, although those treatments can come with a $2 million or more price.

Via MarketBeat

Topics Artificial Intelligence

What 9 Analyst Ratings Have To Say About Biomarin Pharmaceutical ↗

July 27, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 28, 2023 ↗

September 28, 2023

Via Benzinga

4 Awe-Inspiring Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip ↗

September 23, 2023

A nearly 15% decline in the growth-driven Nasdaq Composite from its record high is a blessing in disguise for opportunistic long-term investors.

Via The Motley Fool

Topics Stocks

Benzinga's Top Ratings Upgrades, Downgrades For September 18, 2023 ↗

September 18, 2023

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

September 15, 2023

Via Benzinga

Have Million-Dollar Gene Therapies Finally Reached An Inflection Point? ↗

September 15, 2023

Gene therapies are clearing the FDA and reaching seriously ill patients. They could cost millions.

Via Investor's Business Daily

4 Preeminent Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip ↗

September 02, 2023

The innovation-fueled Nasdaq Composite remains 13% below its all-time high, which means bargains can still be found.

Via The Motley Fool

Topics Stocks

4 Unforgettable Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip ↗

August 12, 2023

With the growth-driven Nasdaq Composite still 14% below its record-closing high, deals abound.

Via The Motley Fool

Topics Stocks

Biomarin's Q2 Beat Street View, Raises Voxzogo Annual Guidance Driven By Global Demand ↗

August 01, 2023

Biomarin Pharmaceutical Inc (NASDAQ: BMRN) reported a Q2 adjusted EPS of $0.54, higher than $0.41 a year ago and beating the

Via Benzinga

Earnings Scheduled For July 31, 2023 ↗

July 31, 2023

Companies Reporting Before The Bell • Immunogen (NASDAQ:IMGN) is estimated to report quarterly loss at $0.16 per share on revenue of $42.84 million.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

16 17 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.